Based on the APELLIS PHARMACT.DL-0001 stock forecast from 0 analysts, the average analyst target price for APELLIS PHARMACT.DL-0001 is not available over the next 12 months. APELLIS PHARMACT.DL-0001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of APELLIS PHARMACT.DL-0001 is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, APELLIS PHARMACT.DL-0001’s stock price was EUR 31.24. APELLIS PHARMACT.DL-0001’s stock price has changed by +2.08% over the past week, +22.23% over the past month and -36.77% over the last year.
No recent analyst target price found for APELLIS PHARMACT.DL-0001
No recent average analyst rating found for APELLIS PHARMACT.DL-0001
Company Overview APELLIS PHARMACT.DL-0001
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Read Less
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the ...Read More
Frequently Asked Questions About APELLIS PHARMACT.DL-0001 (1JK:F) Stock
Stock Target Advisor's fundamental analysis for APELLIS PHARMACT.DL-0001's stock is Slightly Bearish.
Unfortunately we do not have enough data on 1JK:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1JK:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 1JK:F's stock to indicate if its overvalued.
The last closing price of 1JK:F's stock was EUR 31.24.
The most recent market capitalization for 1JK:F is EUR 3.93B.
Unfortunately we do not have enough analyst data on 1JK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains APELLIS PHARMACT.DL-0001's stock.
As per our most recent records APELLIS PHARMACT.DL-0001 has 702 Employees.
APELLIS PHARMACT.DL-0001's registered address is 100 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from APELLIS PHARMACT.DL-0001's website at https://www.apellis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About APELLIS PHARMACT.DL-0001 (1JK:F) Stock
Stock Target Advisor's fundamental analysis for APELLIS PHARMACT.DL-0001's stock is Slightly Bearish.
Unfortunately we do not have enough data on 1JK:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1JK:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 1JK:F's stock to indicate if its overvalued.
The last closing price of 1JK:F's stock was EUR 31.24.
The most recent market capitalization for 1JK:F is EUR 3.93B.
Unfortunately we do not have enough analyst data on 1JK:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains APELLIS PHARMACT.DL-0001's stock.
As per our most recent records APELLIS PHARMACT.DL-0001 has 702 Employees.
APELLIS PHARMACT.DL-0001's registered address is 100 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from APELLIS PHARMACT.DL-0001's website at https://www.apellis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 1JK:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
